Refractory Anemia with Excess Blasts-1
Associated Genetic Biomarkers
NCI Definition: A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood. Approximately 25% of cases progress to an acute leukemia. (WHO) 
There are 2 clinical trials for refractory anemia with excess blasts-1, of which 2 are open and 0 are completed or closed. Of the trials that contain refractory anemia with excess blasts-1 as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Prame-targeting t-cell receptor/inducible caspase 9 bpx-701, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most common interventions in refractory anemia with excess blasts-1 clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.